Kornimate/medical-research-clean huggingface dataset:
the effect of mindfulness-based intervention and haptonomy application on birth self-efficacy, prenatal attachment and anxiety levels of pregnant women with fear of childbirth

Conditions: Fear of Childbirth; Haptonomy; Mindfulness; Self-Efficacy; Attachment

Summary: fear of childbirth is a common condition encountered during pregnancy. women with fear of childbirth have reduced birth self-efficacy, and it leads to mental health problems in the prenatal and postnatal periods, reducing mother-infant bonding. therefore, it is of critical importance to implement effective and applicable interventions focused on health and well-being to reduce fear of childbirth. considering the increasing cesarean section rates today, holistic intervention strategies that can positively affect the birth experiences of pregnant women and support their psychological well-being are needed. in this sense, mindfulness and haptonomy applications, which are holistic intervention strategies, will allow us to meet the psychological and emotional needs of pregnant women with fear of childbirth and improve their birth experiences. no study has been found in the literature that systematically evaluates the effects of a holistic intervention strategy for women with fear of childbirth during pregnancy. this study will enable the development of new and effective intervention strategies that can be used in prenatal and postnatal care practices and will guide clinical practices to make pregnant women's birth experiences more positive. in this study, the effects of mindfulness-based intervention and haptonomy application on childbirth self-efficacy, prenatal attachment and anxiety levels in pregnant women experiencing fear of childbirth will be evaluated. this research will be conducted as a randomized controlled experimental study. the data of the research will consist of 225 women (75 in the mindfulness group, 75 in the haptonomy group, and 75 in the control group) who applied to the erzurum city hospital gynecology and obstetrics clinic between 01.06.2024 and 01.07.2025. the data will be collected face to face using the "personal information form", "wijma childbirth expectation/experience scale version a", "prenatal attachment inventory", and "state anxiety scale".


Eligibility criteria:
inclusion criteria: * being a primary school graduate, * women in their 28th week of pregnancy, * being primigravida, * women with a healthy pregnancy, * women with a wijma childbirth expectation/experience scale version a score of ≥38, * women who agree to participate in the study and do not have any chronic health problems that would prevent them from participating. exclusion criteria: * pregnant women who did not agree to participate in the study or who left the study at any stage of the study will constitute the study.

Keywords: attachment self-efficacy mindfulness haptonomy fear of childbirth
double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of ravulizumab administered intravenously in adult participants at high risk of delayed graft function after kidney transplantation

Conditions: Delayed Graft Function; DGF; Kidney Transplant

Summary: the primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of dgf as measured by time to freedom from dialysis in adult participants who are at high risk of dgf after undergoing transplant of deceased donor kidney.

awake is a multicenter, prospective study to evaluate the safety and efficacy of ravulizumab in reducing delayed graft function (dgf) in kidney transplant recipients at high risk for dgf. eligible participants will be randomized in a 1:1 ratio to receive either ravulizumab or placebo intravenously.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age at the time of signing the informed consent * diagnosed with dialysis-dependent end-stage kidney disease (eskd) * a candidate for kidney transplant from: 1. donation after circulatory death (dcd) donor 2. high-risk donation after brain death (dbd) donor exclusion criteria: * is to receive a kidney from a donor with category i,ii,iv and v maastricht classification * diagnosed with acute kidney injury (aki) of stage 3 severity according to the kidney disease: improving global outcomes (kdigo) guidelines.

Keywords: delayed graft function dgf kidney transplant ravulizumab
rituximab to prevent recurrence of proteinuria

Conditions: FSGS; Proteinuria

Summary: the investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (fsgs). the proposed study has strong clinical implications, since it may extend the approved indications for rituximab treatment to recurrent fsgs as well as to other proteinuric diseases. furthermore, it will offer new insights into the role of sphyngomyelin related enzymes in podocyte function in health and disease, thus allowing the identification of novel targets for antiproteinuric drug development. finally, the proposed study offers the opportunity to identify a correlation between the patient's specific clinical outcome and the experimental results obtained after exposing podocytes to patient sera in the presence or absence of rituximab. therefore, it may lead to the development of an assay for the pre-transplant identification of patients at high-risk for recurrent disease and, among them, may allow the identification of those patients that will respond to rituximab.

a total of 60 patients will be enrolled in the study.

Eligibility criteria:
inclusion: 1. patient has been fully informed and has signed a dated irb-approval informed consent form. 2. age 7-65 years. 3. male and females diagnosed of fsgs by kidney biopsy. kidney biopsy report is not required once the physician confirms the diagnosis. transcribed reports from referring physicians are also valid. exclusion: 1. recipient or donor is seropositive for human immunodeficiency virus (hiv), hepatitis c viruses, or hepatitis b virus antigenemia. 2. patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or carcinoma in situ of the cervix that has been treated successfully. 3. patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable medical condition that could interfere with study objectives. 4. patient is pregnant or lactating. 5. patient has any form of substance abuse, psychiatric disorder or a condition that, in opinion of the investigator, may invalidate communication with the investigator. 6. patients with a defined genetic cause of fsgs.
evaluation of impact of ai assistance on workload associated w preparation of rare tumor case repts

Conditions: Cognitive Burden; Cognitive Symptom

Summary: the goal of this study is to explore cognitive burden perceptions among physicians in relation to case report writing. furthermore, this study evaluates the use of artificial intelligence (ai) assistance as a tool to reduce cognitive burden among providers preparing and submitting case reports. if an ai-tool is helpful in this setting, it may potentially help increase reporting of rare medical events and thereby improve the evidence base for care of these patient populations. this study will occur at a single time point which is expected to last approximately 2 hours. this session will include reviewing two rare tumor cases and then writing a clinical vignette with and without ai assistance.


Eligibility criteria:
inclusion criteria: 1. the subject is a physician, medical student, or postdoctoral student. exclusion criteria:

Keywords: artificial intelligence case report
evaluation of desloratadine when used in patients with either allergic rhinitis or chronic idiopathic urticaria

Conditions: Rhinitis; Urticaria

Summary: eligible patients will be prescribed desloratadine 1 tablet of 5 mg once daily. patients will be asked to follow-up for a final visit after 14 days (day 15) where the safety, tolerability and clinical efficacy will be measured.


Eligibility criteria:
inclusion criteria: * outpatient men or women, age 12 years and above. * diagnosis of allergic rhinitis or chronic idiopathic urticaria exclusion criteria: * known hypersensitivity to desloratadine. * pregnancy or lactation
changes in semen or sperm caused by temozolomide in patients with newly diagnosed, progressive, or recurrent primary malignant brain tumors

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Infertility

Summary: rationale: learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment. purpose: this clinical trial is studying changes in semen or sperm caused by temozolomide in patients with newly diagnosed, progressive, or recurrent primary malignant brain tumors.

objectives: primary * assess if temozolomide induces any changes in standard semen or sperm analysis parameters (i.e., volume, viscosity, ph, forward progression, total count, total motile count, motility, presence of round cells, agglutination, and morphology) in patients with newly diagnosed, recurrent, or progressive primary malignant brain tumors. outline: this is a pilot study. during treatment with temozolomide, patients undergo semen or sperm sample collection at baseline, 3 months, and 6 months for semen analysis. samples are analyzed for volume, viscosity, ph, forward progression, total count, total motile count, motility, presence of round cells, agglutination, and morphology.

Eligibility criteria:
disease characteristics: * histologically confirmed primary malignant brain tumor * newly diagnosed, progressive, or recurrent disease * may have received prior radiotherapy with or without chemotherapy * scheduled to begin single-agent temozolomide chemotherapy * must be able to ejaculate * must abstain from ejaculating (e.g., not have sex or masturbate) for 2-7 days prior to study * no known abnormal sperm motility and/or morphology patient characteristics: * karnofsky performance status 60-100% prior concurrent therapy: * see disease characteristics

Keywords: infertility chemotherapeutic agent toxicity adult anaplastic astrocytoma adult diffuse astrocytoma adult giant cell glioblastoma adult gliosarcoma adult pilocytic astrocytoma adult brain stem glioma adult central nervous system germ cell tumor adult choroid plexus tumor adult craniopharyngioma adult ependymoblastoma adult medulloblastoma adult supratentorial primitive neuroectodermal tumor (pnet) adult anaplastic ependymoma adult ependymoma adult myxopapillary ependymoma adult subependymoma adult anaplastic meningioma meningeal melanocytoma adult meningeal hemangiopericytoma adult papillary meningioma adult grade i meningioma adult grade ii meningioma adult grade iii meningioma adult anaplastic oligodendroglioma adult oligodendroglioma adult pineoblastoma adult pineocytoma adult mixed glioma recurrent adult brain tumor adult subependymal giant cell astrocytoma
capsular tension rings in intraocular lens rotation

Conditions: Cataract; Ophthalmoplegia; Ophthalmologic Complication

Summary: to investigate whether implantation of a capsular tension ring device will affect the degree of rotation of an implanted toric intraocular lens following cataract surgery.

the study is a prospective, subject-blinded investigation of whether implanting capsular tension rings with intraocular lenses affects rotational stability of the lens. lens selection: the patients will undergo standard of care preoperative measurements and planning. the surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the iol power, cylinder, and target axis (standard of care). preoperative measurements will be taken using iol-master 700, with the addition of the pentacam and automatic keratometry as needed (standard of care). the toric lens used will be the tecnis iol. it will be used on label (standard of care). randomization: each eye undergoing cataract surgery will be randomized into a control or treatment group. if both eyes meet enrollment criteria, then each eye will be randomized independently. * control group: toric iol only * treatment group: toric iol plus capsular tension ring

Eligibility criteria:
\*\*patients must be able to get care at nellis air force base (a military installation) in order to participate in this study\*\* inclusion criteria: * active duty and dod beneficiaries aged 30 years or older undergoing cataract surgery * corneal astigmatism ≥ 1.0 d and a surgical plan that includes a toric intraocular lens for astigmatism correction. (the lens used will be the tecnis iol. it will be used on label) * no observed zonular or capsular problems prior to, or at the time of, capsular tension ring insertion exclusion criteria: * patients undergoing cataract surgery who do not have corneal astigmatism ≥1.0 d. * any observed zonular or capsular problems prior to, or at the time of, capsular tension ring insertion. * pre-existing ocular conditions, including:pre-existing ocular conditions, including: * pseudoexfoliation syndrome in one or both eyes * prior incisional ocular surgery * lens subluxation * poor dilation or inability to position at the slit lamp (making postoperative outcome measurements difficult or impossible) * plans for extensive travel or to move away during the postoperative evaluation period * other conditions that would influence the capsule or lens positioning * surgical plan to include other procedures at the time of initial cataract surgery, such as limbal relaxing incisions (lris), micro-incisional glaucoma surgery (migs), etc.

Keywords: ophthalmology capsular tension ring rotation
minimally invasive surgery: using natural orfices

Conditions: Appendicitis; Cholelithiasis; Gallstones

Summary: this is an observational study of pain and outcomes from females undergoing transvaginal notes removal of their appendix or gallbladder. female subjects who elect to have a transvaginal notes removal of their appendix or gallbladder and agree to be in this study (through signature on the informed consent form) will be followed per standard of care, with additional follow-up for data collection including the following: * subjects will complete a 7 day pain/temperature log after surgery * subjects will complete a standardized sexual function questionnaire (female sexual function index) prior to surgery and 6 months after surgery * subjects will receive a phone call at 6 months and at 1 year after surgery to capture data related to safety, adverse events, hospitalizations and patient satisfaction additional data related to pain and outcomes will be collected at baseline/screening and at follow-up as necessary.


Eligibility criteria:
inclusion criteria for transvaginal appendectomy: 1. females between the ages of 18-75 2. clinical diagnosis of appendicitis 3. emergency room evaluation within 36 hours of the onset of pain 4. asa classification 1 5. mentally competent to give informed consent 6. scheduled to undergo a transvaginal notes appendectomy. exclusion criteria for transvaginal appendectomy: 1. pregnant women (need to have negative icon in er) 2. morbidly obese patients (bmi \>35) 3. patients who are taking immunosuppressive medications or are immunocompromised 4. patients with evidence of an abdominal abscess or mass 5. patients who present with a clinical diagnosis of sepsis or peritonitis 6. patients who have a history of prior transvaginal surgery. patients with prior laparoscopic surgery will be included. 7. patients who endorse a history of ectopic pregnancy, pelvic inflammatory disease (pid), or severe endometriosis 8. patients with diffuse peritonitis on clinical exam 9. patients on blood thinners or aspirin or abnormal blood coagulation tests inclusion criteria for transvaginal cholecystectomy: 1. females between the ages of 18 and 75 2. diagnosis of gallstone disease which requires cholecystectomy 3. asa class 1 4. mentally competent to give informed consent 5. scheduled to undergo a transvaginal notes cholecystectomy exclusion criteria for transvaginal cholecystectomy: 1. pregnant women 2. morbidly obese patients (bmi \> 35) 3. patients who are taking immunosuppressive medications and/or immunocompromised 4. patients with severe medical comorbidities will be excluded. 5. patients with a presumed gallbladder polyps, mass or tumor 6. patients with a history of prior transvaginal surgery. patients with prior laparoscopic surgery will be included. 7. patients with a history of ectopic pregnancy, pelvic inflammatory disease, or severe endometriosis 8. patients with known common bile duct stones 9. patients on blood thinners or aspirin or abnormal blood coagulation tests

Keywords: appendicitis cholelithiasis gallstones
effect of an outpatient intervention program in patients with chronic back or neck pain

Conditions: Chronic Low Back Pain; Neck Pain

Summary: to investigated whether an ambulant intervention program with a behavioral therapy approach would exert a long-term effect on chronic unspecific back or neck pain. specifically, the effect on patients with pronounced fear avoidance behavior and/or with psychosocial limitations was addressed.

background: sustained success of ambulant intervention programs consisting of individual and group physiotherapy in patients with with chronic unspecific back or neck pain (cbp) has not been conclusively proven. it's still not clear whether one can achieve such success by devoting greater attention to psychosocial factors. objective: we investigated whether an ambulant intervention program with a behavioral therapy approach would exert a long-term effect on cbp. specifically, the effect on patients with pronounced fear avoidance behavior and/or with psychosocial limitations was addressed. design: prospective, randomized controlled trial settings, intervention: 64 patients were assigned to intervention group (ig) and 57 to control group (cg). all were examined, informed about cbp, and were encouraged to stay active and perform exercises according to specific instructions provided in a neck- or back-book. the ig received 9 units of physiotherapy and 2 units of occupational therapy, conducted with a behavioral therapy approach. efficacy of treatment was evaluated after 6 and 58 weeks. measurements: pain (vas), quantity of painkillers consumed, sick leave days, oswestry-disability-index (odi), sf-36, fabq.

Eligibility criteria:
inclusion criteria: * minimum age 18 years, maximum age: men 55 years, women 50 years. * the patients had been on sick leave for a minimum of 4 and a maximum of 22 days during the preceding 12 months because of nonspecific spinal symptoms in the back or neck. * the patients had to be working at the start of the study. exclusion criteria: * specific causes of spinal symptoms (after spinal surgery, known vertebral body fractures, disk prolapse with motor deficits or other radicular lesions, tumor, osteomyelitis, spondylodiscitis, rheumatic disease, osteoporosis). * retired persons, those in the process of being screened for retirement, unemployed persons, * pregnancy or persons on maternity leave * planned surgery during the phase of intervention * persons who were unable to participate in the intervention program for other reasons (physical, psychological, linguistic or organizational).

Keywords: outpatient intervention program behavioral therapy approach unspecific back pain unspecific neck pain chronic pain physiotherapy occupational therapy psychosocial aspects fear avoidance beliefs health-related quality of life
evolocumab versus ldl apheresis in patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: an open-label, prospective phase iii study to compare the efficacy and safety of administering evolocumab versus treatment with ldlapheresis in patients with familial hypercholesterolemia and high cardiovascular risk.

study design an open-label, prospective phase iii study to compare the efficacy and safety of administering evolocumab versus treatment with ldlapheresis in patients with familial hypercholesterolemia and high cardiovascular risk. study population the chosen population is constituted by patients belonging to the ldl-apheresis program of the general university hospital gregorio marañón with the diagnosis of familial hypercholesterolemia and a history of cardiovascular disease. number of patients expected to participate in the study according to the base of patients treated with ldl-apheresis: 10. study design: non-controlled intervention study to evaluate the different therapies in the treatment of hypercholesterolemia, in which each patient will be self-controlled. the variables will be analyzed during different phases 1. ldl-apheresis phase: retrospectively during the previous year, pre- and postapheresis variables will be collected from the following lipid parameters: total cholesterol, ldl-cholesterol, hdl-cholesterol, triglycerides, atherogenicity index, lipoprotein a, apo-a, apo- b; inflammatory parameters: pcr, ferritin, fibrinogen, leukocytes and polymorphonuclear and immunological parameters: immunoglobulins and complement. 2. evolocumab phase: ldl-apheresis will be suspended for three months and evolocumab administered: 140 mg / 15 days subcutaneously. the same parameters indicated in the previous section will be measured every two weeks. 3. combined phase: during the following three months evolocumab will continue to be administered biweekly and the ldl-apheresis procedure will be spaced from biweekly to monthly, the same analytical parameters being measured again every two weeks.

Eligibility criteria:
inclusion criteria: * patients with age\> 18 years * hypercholesterolemia with ldl-cholesterol\> 100 mg / dl in treatment with the maximum dose tolerated by statins and a history of severe cardiovascular disease * patients who are included in the ldl-apheresis / biweekly program exclusion criteria: * contraindications to receive evolocumab according to technical data. * hospital admission of any cause in the last three months prior to the inclusion of the study * cardiovascular event in the three months prior to the inclusion of the study * inability to sign informed consent * pregnant women and non-menopausal women who do not use at least one adequate contraceptive method

Keywords: cardiovascular risk evolocumab ldl-apheresis
study of the effect of transcranial stimulations in aphasic subject within a year of their stroke

Conditions: Aphasia; Stroke

Summary: the aim of this work is to study the effect of transcranial direct current stimulation combined with naming therapy in acute and post-acute stroke comparing four bihemispheric positioning electrodes to a sham condition.

tdcs have shown a positive effect on clinical outcome in naming treatment in aphasic subjects however some aspects as the positioning of the electrodes on the head are still unclear. that is why we compare the effects of four different positionings of the electrodes (two anterior over broca's area and its homologue and two posterior over wernicke's area and its homologue) to a sham stimulation in order to observe if a more important effect of one or another positioning could be found.

Eligibility criteria:
inclusion criteria: * man or woman of 18 years and older * aphasic patient following a first left hemispheric stroke * bdae 3.0 aphasia score \> or = to 1 * stroke within 3 to 12 months before inclusion in the study * mother tongue = french * right handedness * signed informed consent exclusion criteria: * history of other neurologic pathologies * epileptic seizure within 2 months before inclusion * dementia * bilingual patient (2 mother tongues) * history of cranial surgery * presence of intracerebral metallic material * unauthorized molecules at inclusion : sulpiride, rivastigmine, dextromethorphan, carbamazepine, flunarizine, levodopa * pregnant, parturient or lactating woman

Keywords: tdcs stroke aphasia naming